Tag Archives: case

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients

With an approval filing already on the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients after surgery. In long-term data from its pivotal trial in peripheral artery disease, Xarelto plus aspirin cut the risk of a variety of clot-related episodes—acute clots in the limbs, a major… Read More »